Discovery of new therapeutic targets for aggressive prostate cancer
This project aims to discover new therapeutic targets for a particularly aggressive and therapy resistant form of prostate cancer known as Neuroendocrine prostate cancer (NEPC). Current clinical therapies are not effective at inhibiting the growth and spread of NEPC and men diagnosed with NEPC have a very poor prognosis. It is hoped that findings from our study will reveal new therapeutic strategies to specifically kill this form of prostate cancer and improve outcomes for men with NEPC.
Investigators
| Brett Hollier | APCRC-Q, IHBI, QUT, TRI |
| Brian Gabrielli | Mater Research Institute, UQ, TRI |
| Ian Vela | APCRC-Q, IHBI, QUT, TRI, PAH |
Duration
2018 - 2018
Funding
| Prostate Cancer Foundation of Australia | $100 000 |
